drugset / Trial / NCT04553133
PF-07104091 as a Single Agent and in Combination Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | TEGTOCICLIB | Small molecule | — | Oral |